281 related articles for article (PubMed ID: 28835467)
1. DNA repair factor RAD18 and DNA polymerase Polκ confer tolerance of oncogenic DNA replication stress.
Yang Y; Gao Y; Mutter-Rottmayer L; Zlatanou A; Durando M; Ding W; Wyatt D; Ramsden D; Tanoue Y; Tateishi S; Vaziri C
J Cell Biol; 2017 Oct; 216(10):3097-3115. PubMed ID: 28835467
[TBL] [Abstract][Full Text] [Related]
2. Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest.
Bi X; Barkley LR; Slater DM; Tateishi S; Yamaizumi M; Ohmori H; Vaziri C
Mol Cell Biol; 2006 May; 26(9):3527-40. PubMed ID: 16611994
[TBL] [Abstract][Full Text] [Related]
3. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
4. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
5. Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells.
Tirman S; Quinet A; Wood M; Meroni A; Cybulla E; Jackson J; Pegoraro S; Simoneau A; Zou L; Vindigni A
Mol Cell; 2021 Oct; 81(19):4026-4040.e8. PubMed ID: 34624216
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
Geenen JJJ; Schellens JHM
Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
[TBL] [Abstract][Full Text] [Related]
8. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
9. Wee1 kinase as a target for cancer therapy.
Do K; Doroshow JH; Kummar S
Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
[TBL] [Abstract][Full Text] [Related]
10. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
11. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
12. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
13. RAD18 activates the G2/M checkpoint through DNA damage signaling to maintain genome integrity after ionizing radiation exposure.
Sasatani M; Xu Y; Kawai H; Cao L; Tateishi S; Shimura T; Li J; Iizuka D; Noda A; Hamasaki K; Kusunoki Y; Kamiya K
PLoS One; 2015; 10(2):e0117845. PubMed ID: 25675240
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
16. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
17. RAD18 Is a Maternal Limiting Factor Silencing the UV-Dependent DNA Damage Checkpoint in Xenopus Embryos.
Kermi C; Prieto S; van der Laan S; Tsanov N; Recolin B; Uro-Coste E; Delisle MB; Maiorano D
Dev Cell; 2015 Aug; 34(3):364-72. PubMed ID: 26212134
[TBL] [Abstract][Full Text] [Related]
18. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
Schmidt M; Rohe A; Platzer C; Najjar A; Erdmann F; Sippl W
Molecules; 2017 Nov; 22(12):. PubMed ID: 29168755
[TBL] [Abstract][Full Text] [Related]
19. NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis.
Yanagihara H; Kobayashi J; Tateishi S; Kato A; Matsuura S; Tauchi H; Yamada K; Takezawa J; Sugasawa K; Masutani C; Hanaoka F; Weemaes CM; Mori T; Zou L; Komatsu K
Mol Cell; 2011 Sep; 43(5):788-97. PubMed ID: 21884979
[TBL] [Abstract][Full Text] [Related]
20. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
